Discontinued — last reported Q2 '23
Humana Acquisitions increased by 1098.7% to $911.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -73.2% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.05B | $1.05B | $1.05B | $74.00M | $93.00M | $73.00M | $116.00M | $34.00M | $10.00M | $14.00M | $3.00M | $20.00M | $52.00M | $0.00 | $1.00M | $4.00M | $76.00M | $911.00M |
| QoQ Change | — | +0.0% | +0.0% | -92.9% | +25.7% | -21.5% | +58.9% | -70.7% | -70.6% | +40.0% | -78.6% | +566.7% | +160.0% | -100.0% | — | +300.0% | >999% | >999% |
| YoY Change | — | — | — | — | -91.1% | -1.4% | +24.7% | — | — | -80.8% | -97.4% | -41.2% | +420.0% | -100.0% | -66.7% | -80.0% | +46.2% | — |